, Tracking Stock Market Picks
Enter Symbol:
Autodesk, Inc. (ADSK) [hlAlert]

down 3.04 %

Autodesk, Inc. (ADSK) rated Overweight by Morgan Stanley

Posted on: Monday,  Jan 13, 2014  8:25 AM ET by Morgan Stanley

Morgan Stanley rated Overweight Autodesk, Inc. (NASDAQ: ADSK) on 01/13/2014, when the stock price was $51.57. Since
then, Autodesk, Inc. has lost 3.04% as of 11/20/2015's recent price of $50.00.
If you would have followed this Morgan Stanley's recommendation on ADSK, you would have lost 3.04% of your investment in 676 days.

Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson?s disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.

Morgan Stanley Investment Research is one of the financial industry's dominant thought leaders in equity and fixed-income investing. Our analysts, economists, and strategists have earned this reputation through timely, in-depth analysis of companies, industries, markets, and the world’s economies. Our teams collaborate to assist Morgan Stanley clients with investment decisions, using cash and derivative instruments across major asset classes and geographies.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/13/2014 8:25 AM Buy
as of 10/17/2014
1 Week down  -5.45 %
1 Month down  -7.46 %
3 Months down  -8.35 %
1 YTD down  -1.51 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy